Yuan Maoling, Wang Lei, Huang Hao, Li Yuan, Zheng Xiao, Shao Qi, Jiang Jingting
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
Cancer Immunotherapy Engineering Research Center of Jiangsu Province, Changzhou, Jiangsu Province, China.
Biosci Rep. 2021 Mar 26;41(3). doi: 10.1042/BSR20204425.
Interleukin-1 receptor type II (IL-1R2), also known as CD121b, is a member of the IL-1 receptor family. IL-1R2 acts as negative regulator of the IL-1 system, modulating IL-1 availability for the signaling receptor. IL-1R2 is abnormally expressed in many human inflammatory diseases and cancers, and has important clinical significance. The present study was designed to investigate IL-1R2 expression in human gastric cancer (GC) tissues and the associated clinical implications.
Immunohistochemistry was used to identify the clinical significance and prognostic value of IL-1R2 expression in GC tissues. We investigated IL-1R2 expression in GC tissues, cells, and serum using real-time PCR (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) assays.
IL-1R2 was highly expressed in GC tissues, and the overall survival in patients with advanced GC and high IL-1R2 expression was significantly poorer than that in patients with advanced GC and low IL-1R2 expression. Moreover, IL-1R2 mRNA levels in GC tissues and most GC cells were higher than those in para-cancer tissues and GES1 human gastric mucosal epithelial cells. The level of plasma-soluble IL-1R2 in GC patients was higher than that of the healthy control group.
Increased IL-1R2 levels are involved in the initiation and progression of human GC, and IL-1R2 might be employed to develop immunotherapeutic approaches targeting GC.
白细胞介素-1受体II型（IL-1R2），也称为CD121b，是IL-1受体家族的成员。IL-1R2作为IL-1系统的负调节因子，调节信号受体可利用的IL-1。IL-1R2在许多人类炎症性疾病和癌症中异常表达，具有重要的临床意义。本研究旨在调查IL-1R2在人胃癌（GC）组织中的表达及相关临床意义。
采用免疫组织化学法确定IL-1R2在GC组织中的临床意义和预后价值。我们使用实时荧光定量聚合酶链反应（RT-PCR）和酶联免疫吸附测定（ELISA）检测GC组织、细胞和血清中的IL-1R2表达。
IL-1R2在GC组织中高表达，晚期GC且IL-1R2高表达患者的总生存期明显短于晚期GC且IL-1R2低表达患者。此外，GC组织和大多数GC细胞中的IL-1R2 mRNA水平高于癌旁组织和GES1人胃黏膜上皮细胞。GC患者血浆可溶性IL-1R2水平高于健康对照组。
IL-1R2水平升高与人GC的发生和进展有关，IL-1R2可能用于开发针对GC的免疫治疗方法。
